Overview
- The High Court began hearing on June 24 a judicial review of the Care Quality Commission’s decision to register and rate Gender Plus Hormone Clinic as outstanding.
- Claimants including former Tavistock clinician Susan Evans argue the clinic prescribes cross-sex hormones to 16- and 17-year-olds without the multi-disciplinary team approvals mandated by NHS England guidelines.
- The government-commissioned Cass Review in 2024 concluded there is insufficient evidence to support routine hormone treatment for young people, prompting NHS England to require second opinions before prescribing cross-sex hormones or puberty blockers.
- A CQC spokesperson states Gender Plus met all regulatory conditions when it registered the clinic on January 9, 2024, and that its outstanding rating reflected strong risk management and patient safeguards.
- Critics warn that removing regulated status could force trans adolescents to endure years-long NHS waits, seek unregulated private services, or self-medicate, potentially increasing health risks.